Karen S. Lynch - Feb 12, 2024 Form 4 Insider Report for CVS HEALTH Corp (CVS)

Role
President and CEO, Director
Signature
/s/ Karen S. Lynch
Stock symbol
CVS
Transactions as of
Feb 12, 2024
Transactions value $
$0
Form type
4
Date filed
2/14/2024, 05:08 PM
Previous filing
May 5, 2023
Next filing
Apr 3, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CVS Common Stock Award $0 +137K $0.00 137K Feb 12, 2024 Direct F1
holding CVS Common Stock (By Trust) 431K Feb 12, 2024 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
holding CVS Stock Appreciation Rights 193K Feb 12, 2024 Common Stock 193K $45.91 Direct F2
holding CVS Stock Appreciation Rights 94K Feb 12, 2024 Common Stock 94K $37.91 Direct F3, F4
holding CVS Stock Option 242K Feb 12, 2024 Common Stock 242K $54.19 Direct F5
holding CVS Stock Option 211K Feb 12, 2024 Common Stock 211K $58.34 Direct F6, F7
holding CVS Stock Option 225K Feb 12, 2024 Common Stock 225K $74.30 Direct F8
holding CVS Stock Option 172K Feb 12, 2024 Common Stock 172K $101.09 Direct F9
holding CVS Stock Option 245K Feb 12, 2024 Common Stock 245K $74.31 Direct F10
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents shares earned by the reporting person pursuant to certain performance stock units (the "PSUs"), which were granted to the reporting person under the Issuer's 2017 Incentive Compensation Plan on April 1, 2021. The PSUs were earned based on the attainment of certain performance metrics, which performance metrics were certified by the Management and Planning Committee of the Board of Directors of the Issuer on February 12, 2024.
F2 Represents Aetna Inc. Stock Appreciation Rights ("SARs") granted under the Aetna Inc. 2010 Incentive Plan (the "Aetna Plan") on February 17, 2017 that were converted into CVS Health SARs in November 2018 pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested in two substantially equal annual installments beginning on February 17, 2019.
F3 Represents SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs in November 2018 pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F4 Represents unvested SARs granted under the Aetna Plan on February 19, 2016 that were converted into CVS Health SARs pursuant to the terms of the CVS/Aetna Merger Agreement. These SARs vested on February 19, 2019.
F5 Option became exercisable in four equal annual installments, commencing 4/1/2020.
F6 The number of shares subject to the option were calculated using a 30-day average price.
F7 Option became exercisable in four equal installments, commencing 4/1/2021.
F8 Option became exercisable in four equal installments, commencing 4/1/2022.
F9 Option became exercisable in four equal installments, commencing 4/1/2023.
F10 Option becomes exercisable in four equal annual installments, commencing 4/1/2024.